D. Scott Ernst

5.8k total citations · 1 hit paper
77 papers, 4.3k citations indexed

About

D. Scott Ernst is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, D. Scott Ernst has authored 77 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in D. Scott Ernst's work include Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (15 papers). D. Scott Ernst is often cited by papers focused on Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (15 papers). D. Scott Ernst collaborates with scholars based in Canada, United States and Japan. D. Scott Ernst's co-authors include Malcolm J. Moore, David Osoba, Peter Venner, I. F. Tannock, A. J. Neville, Jonathan J. Wilson, George Armitage, C Coppin, Martin R. Stockler and Ian F. Tannock and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

D. Scott Ernst

73 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 1.2k citations I. F. Tannock, David Osoba et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by D. Scott Ernst

Since Specialization

Citations

This map shows the geographic impact of D. Scott Ernst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scott Ernst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scott Ernst more than expected).

Fields of papers citing papers by D. Scott Ernst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Scott Ernst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scott Ernst. The network helps show where D. Scott Ernst may publish in the future.

Co-authorship network of co-authors of D. Scott Ernst

This figure shows the co-authorship network connecting the top 25 collaborators of D. Scott Ernst. A scholar is included among the top collaborators of D. Scott Ernst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Scott Ernst. D. Scott Ernst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens 2024 ·The Oncologist ·Eddy Saad, Georges Gebrael, (unknown), (unknown), Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J. Connor Wells, Kosuke Takemura, (unknown), (unknown), Naveen S. Basappa, Lori Wood, Thomas Powles, D. Scott Ernst, Aly‐Khan A. Lalani, Neeraj Agarwal, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri	0
2	Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma 2023 ·European Urology ·(unknown), Vishal Navani, J. Connor Wells, Frede Donskov, Naveen S. Basappa, Chris Labaki, Sumanta K. Pal, Luís Meza, Lori Wood, D. Scott Ernst, Bernadett Szabados, Rana R. McKay, Francis Parnis, Cristina Suárez, Takeshi Yuasa, Aly‐Khan A. Lalani, Ajjai Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y.C. Heng	33
3	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma 2020 ·European Urology ·Bimal Bhindi, Jeffrey Graham, J. Connor Wells, Ziad Bakouny, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Naveen S. Basappa, Aaron R. Hansen, Christian Kollmannsberger, Ravindran Kanesvaran, Takeshi Yuasa, D. Scott Ernst, Sandy Srinivas, Brian I. Rini, I. Alex Bowman, Sumanta K. Pal, Toni K. Choueiri, Daniel Y.C. Heng	42
4	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 2019 ·European Urology Oncology ·Jeffrey Graham, J. Connor Wells, Frede Donskov, Jae‐Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta, I. Alex Bowman, Georg A. Bjarnason, D. Scott Ernst, Sun Young Rha, Benoit Beuselinck, Aaron R. Hansen, Scott North, Christian Kollmannsberger, Lori Wood, Ulka N. Vaishampayan, Sumanta K. Pal, Toni K. Choueiri, Daniel Y.C. Heng	31
5	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial 2019 ·European Journal of Cancer ·Georg A. Bjarnason, Jennifer J. Knox, Christian Kollmannsberger, Denis Soulières, D. Scott Ernst, Paweł Zalewski, Christina M. Canil, Eric Winquist, Sébastien J. Hotte, Scott North, Daniel Yick Chin Heng, Robyn Jane Macfarlane, Peter Venner, Anil Kapoor, Aaron R. Hansen, Bernhard J. Eigl, Piotr Czaykowski, (unknown), Lisa Wang, Naveen S. Basappa	24
6	Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas 2018 ·Clinical Cancer Research ·John A. Thompson, Robert J. Motzer, Ana M. Molina, Toni K. Choueiri, Elisabeth I. Heath, Bruce G. Redman, Randeep Sangha, D. Scott Ernst, Роберто Пили, Stella K. Kim, Leonard Reyno, (unknown), Fabio Trave, Banmeet S. Anand, Karen Morrison, Fernando Doñate, Christian Kollmannsberger	48
7	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category 2016 ·European Urology ·Ian D. Davis, Wanling Xie, Carmel Pezaro, Frede Donskov, J. Connor Wells, Neeraj Agarwal, Sandy Srinivas, Takeshi Yuasa, Benoit Beuselinck, Lori Wood, D. Scott Ernst, Ravindran Kanesvaran, Jennifer J. Knox, Allan J. Pantuck, Sadia Saleem, Ajjai Alva, Brian I. Rini, Jae‐Lyun Lee, Toni K. Choueiri, Daniel Y.C. Heng	8
8	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 2016 ·European Urology ·J. Connor Wells, Igor Stukalin, Craig Norton, Sandy Srinivas, Jae‐Lyun Lee, Frede Donskov, Georg A. Bjarnason, Haru Yamamoto, Benoit Beuselinck, Brian I. Rini, Jennifer J. Knox, Neeraj Agarwal, D. Scott Ernst, Sumanta K. Pal, Lori Wood, Aristotelis Bamias, Ajjai Alva, Ravindran Kanesvaran, Toni K. Choueiri, Daniel Y.C. Heng	58
9	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial 2015 ·The Lancet Oncology ·Nicole Basset‐Séguin, Axel Hauschild, Jean‐Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Laurent Mortier, (unknown), Lisa Licitra, Caroline Dutriaux, L. Thomas, Thomas Jouary, Nicolás Meyer, B. Guillot, Reinhard Dummer, Kate Fife, D. Scott Ernst, Sarah Williams, A. Fittipaldo, Ioannis Xynos, Johan Hansson	170
10	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study 2015 ·The Lancet Oncology ·Jenny J. Ko, Wanling Xie, Nils Kroeger, (unknown), Brian I. Rini, Jennifer J. Knox, Georg A. Bjarnason, Sandy Srinivas, Sumanta K. Pal, Takeshi Yuasa, Martin Smoragiewicz, Frede Donskov, Ravindran Kanesvaran, Lori Wood, D. Scott Ernst, Neeraj Agarwal, Ulka N. Vaishampayan, Sun Young Rha, Toni K. Choueiri, Daniel Y.C. Heng	288
11	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 2014 ·European Urology ·Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini, Benoit Beuselinck, Jae‐Lyun Lee, Jennifer J. Knox, Georg A. Bjarnason, Sumanta K. Pal, Christian Kollmannsberger, Takeshi Yuasa, Sandy Srinivas, Frede Donskov, Aristotelis Bamias, Lori Wood, D. Scott Ernst, Neeraj Agarwal, Ulka N. Vaishampayan, Sun Young Rha, Jaeyeon Kim, Toni K. Choueiri	311
12	Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours 2012 ·Canadian Urological Association Journal ·(unknown), D. Scott Ernst, Larry Stitt, Eric Winquist	3
13	Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy 2005 ·Prostate Cancer and Prostatic Diseases ·(unknown), John C. Saliken, D. Scott Ernst, Bryce Weber, John W. Robinson, Penny Brasher, Mary Ann Rose, John C. Rewcastle	46
14	Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma 2005 ·Investigational New Drugs ·D. Scott Ernst, Elizabeth A. Eisenhauer, Nancy Wainman, M. L. Davis, Reinhard Lohmann, Tara Baetz, Karl Bélanger, Michael Smylie	89
15	Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract 2003 ·European Journal of Cancer ·Eric Winquist, D. Scott Ernst, (unknown), Malcolm J. Moore, Roanne Segal, G. Lockwood, (unknown)	17
16	Prospective trial of cryosurgical ablation of the prostate: five-year results 2002 ·Urology ·Bryan Donnelly, John C. Saliken, D. Scott Ernst, (unknown), Penny Brasher, John W. Robinson, John C. Rewcastle	106
17	A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer 2001 ·Annals of Oncology ·Anthony Dowling, Tony Panzarella, D. Scott Ernst, A. J. Neville, Malcolm J. Moore, I. F. Tannock	17
18	Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. 1997 ·Journal of Clinical Oncology ·Malcolm J. Moore, Ian F. Tannock, D. Scott Ernst, S. Huan, Nevin Murray	222
19	Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. breakdown → 1996 ·Journal of Clinical Oncology ·I. F. Tannock, David Osoba, Martin R. Stockler, D. Scott Ernst, A. J. Neville, Malcolm J. Moore, George Armitage, Jonathan J. Wilson, Peter Venner, C Coppin, (unknown)	1202
20	Treatment of skeletal disease in breast cancer with clodronate 1991 ·Bone ·Alexander Paterson, D. Scott Ernst, T.J. Powles, S. Ashley, Eugène McCloskey, John А. Kanis	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact